MIRATI THERAPEUTICS INC(NASDAQ:MRTX) stock News

MRTX Latest News, Press Relases and Analysis

All

Press Releases

2 years ago - By: Seeking Alpha - Mentions: BMY KRTX RYZB

Bristol Myers stock cut at Redburn Atlantic (NYSE:BMY)

2 years ago - By: Bloomberg - Mentions: TSLA BMY

Billionaire Joe Lewis Nets 730% Gain on Stock Behind US Charges

2 years ago - By: Seeking Alpha - Mentions: BMY

Bristol Myers Squibb closes Mirati acquisition (NYSE:BMY)

2 years ago - By: Seeking Alpha - Mentions: BMY

Bristol Myers Squibb completes Mirati acquisition (NYSE:BMY)

2 years ago - By: Seeking Alpha - Mentions: BMY

Mirati's Krazati gets EU conditional approval for lung cancer (NASDAQ:MRTX)

2 years ago - By: Benzinga

Analyst Expectations For Mirati Therapeutics's Future

2 years ago - By: Benzinga

What 11 Analyst Ratings Have To Say About Mirati Therapeutics

2 years ago - By: Seeking Alpha - Mentions: BMY JPM KRTX RYZB

Bristol-Myers looking for smaller deals after 2023 shopping spree: report (NYSE:BMY)

2 years ago - By: Seeking Alpha - Mentions: BMY BAC KRTX RYZB

Bristol-Myers Squibb stock cut to Neutral at BofA (NYSE:BMY)

2 years ago - By: Seeking Alpha - Mentions: AMGN BMY

Amgen says FDA snubbed full approval for Lumakras

2 years ago - By: Seeking Alpha - Mentions: BMY

Mirati Therapeutics stock gains as HSR waiting period for sale to Bristol-Myers expires

2 years ago - By: Bloomberg

Billionaire Joe Lewis Keeps Trading Stocks Behind US Insider-Trading Charges

2 years ago - By: InvestorPlace - Mentions: BMY HPQ O TEVA ...

3 Resilient Stocks with Massive Potential to Boost Your Wealth

2 years ago - By: BusinessInsider - Mentions: PFE CERE BCSF

3 Biotech Stocks That Could Boom or Bust by 2025

2 years ago - By: InvestorPlace - Mentions: XBI CERE RVMD VCEL

3 Biotech Stocks That Could Boom or Bust by 2025

2 years ago - By: Seeking Alpha

Mirati lung cancer therapy endorsed in EU (NASDAQ:MRTX)

2 years ago - By: Mirati Therapeutics, Inc.

Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure

2 years ago - By: Kahn Swick & Foti, LLC

MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX

2 years ago - By: The Motley Fool - Mentions: NEE MO BMY NEP

3 No-Brainer Stocks to Buy With $500 Right Now

2 years ago - By: Mirati Therapeutics, Inc.

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

2 years ago - By: Seeking Alpha - Mentions: BMY

Bristol-Myers was only firm that made real bid for Mirati Therapeutics

2 years ago - By: Seeking Alpha - Mentions: BMY SNY

Bristol-Myers was only firm that made real offer for Mirati Therapeutics

2 years ago - By: InvestorPlace - Mentions: JNJ KVUE MCK WBA ...

7 Healthcare Stocks That Can Cure a Lackluster Portfolio

2 years ago - By: Mirati Therapeutics, Inc.

Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)

2 years ago - By: Brodsky & Smith LLC - Mentions: CNSL PXD SUM BMY ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq – CNSL), Mirati Therapeutics, Inc.® (Nasdaq - MRTX), Pioneer Natural Resources (NYSE - PXD), Summit Materials (NYSE

2 years ago - By: Investor's Business Daily - Mentions: AMGN BMY

MIRATI THERAPEUTICS INC (MRTX) Stock News

MRTX Latest News, Press Relases and Analysis

Bristol Myers stock cut at Redburn Atlantic (NYSE:BMY)

Billionaire Joe Lewis Nets 730% Gain on Stock Behind US Charges

Bristol Myers Squibb closes Mirati acquisition (NYSE:BMY)

Bristol Myers Squibb completes Mirati acquisition (NYSE:BMY)

Mirati's Krazati gets EU conditional approval for lung cancer (NASDAQ:MRTX)

Analyst Expectations For Mirati Therapeutics's Future

What 11 Analyst Ratings Have To Say About Mirati Therapeutics

Bristol-Myers looking for smaller deals after 2023 shopping spree: report (NYSE:BMY)

Bristol-Myers Squibb stock cut to Neutral at BofA (NYSE:BMY)

Amgen says FDA snubbed full approval for Lumakras

Mirati Therapeutics stock gains as HSR waiting period for sale to Bristol-Myers expires

Billionaire Joe Lewis Keeps Trading Stocks Behind US Insider-Trading Charges

3 Resilient Stocks with Massive Potential to Boost Your Wealth

3 Biotech Stocks That Could Boom or Bust by 2025

3 Biotech Stocks That Could Boom or Bust by 2025

Mirati lung cancer therapy endorsed in EU (NASDAQ:MRTX)

Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure

MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX

3 No-Brainer Stocks to Buy With $500 Right Now

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Bristol-Myers was only firm that made real bid for Mirati Therapeutics

Bristol-Myers was only firm that made real offer for Mirati Therapeutics

7 Healthcare Stocks That Can Cure a Lackluster Portfolio

Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq – CNSL), Mirati Therapeutics, Inc.® (Nasdaq - MRTX), Pioneer Natural Resources (NYSE - PXD), Summit Materials (NYSE

Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected Upgrade